Suppression of endometrial matrix metalloproteinases (MMPs) is necessary to maintain tissue stability during the invasive events of implantation and placental development. Several laboratories have shown that inflammatory cytokines, including interleukin-1␣ (IL-1␣), can oppose progesterone suppression of MMPs in the human endometrium. Furthermore, we have recently demonstrated colocalization of epithelial cell IL-1␣ and MMP-7 expression at sites of ectopic pregnancy. The current study extends these findings, revealing a previously unrecognized interrelationship between progesterone and IL-1␣ in regulation of MMP-3. Although IL-1␣ is a potent stimulator of MMP-3 in proliferative phase endometrium in organ culture, we demonstrate that progesterone exposure in vivo reduces IL-1␣ stimulation of MMP-3 in secretory phase tissue. This loss of sensitivity to IL-1␣ was duplicated in isolated stromal cells treated with progesterone in vitro, and IL-1␣ stimulation of MMP-3 returned in a dosedependent manner with progesterone withdrawal. The antiprogestin, onapristone, partially blocked the ability of progesterone to prevent stimulation of MMP-3 by IL-1␣. These data suggest a novel mechanism by which progesterone may preserve tissue integrity during the establishment and maintenance of pregnancy by limiting stimulation of MMPs by inflammatory cytokines such as IL-1␣. (J Clin Endocrinol
T HE HUMAN ENDOMETRIUM is a highly specialized
tissue that has evolved for the sole purpose of establishing and maintaining pregnancy. In the adult, cyclical production of ovarian estradiol and progesterone directs a predictable pattern of endometrial growth and functional maturation. The rise in postovulatory serum progesterone levels signals endometrial differentiation, which culminates in a state of receptivity for implantation (1) (2) (3) . After invasion of fetal trophoblast cells beyond the epithelial barrier, progesterone action at the maternal-fetal interface remains critical for normal placental development. Failure of progesterone to support differentiation of the endometrial stroma, known as decidualization, is linked to gestational failure and early loss of pregnancy (4) . Establishing a viable pregnancy is a biologically complex process, and numerous cytokines are equally important, working with steroids to mediate cell-cell communication between the diverse cell types present within the endometrium and developing placenta (5) (6) (7) (8) .
Providing nourishment within a protective environment is the primary function of the hemochorial placenta, a unique structure dependent upon stable and predictable interactions between cells of diverse origin. Development of this transient organ, however, involves invasive events that are facilitated by potentially destructive proteolytic enzymes (9) . The secretion of cell-specific matrix metalloproteinases (MMPs), including MMP-9 and MMP-2, mediate trophoblast cell invasion through the extracellular matrix of the endometrial stroma and subsequent fusion with the maternal vasculature (10, 11) . However, maintaining uterine tissue integrity during the disruptive events of implantation and placentation requires that the expression of MMPs by maternal cells be limited (12) (13) (14) . The cellular and molecular mechanisms by which steroids and cytokines act together to promote the selective expression of specific MMPs while limiting the actions of others during the establishment of pregnancy are not well understood. Several laboratories, including ours, have focused efforts on understanding the interactions of steroids and cytokines in the endometrium, with particular regard to the regulation of MMP expression by progesterone (15) (16) (17) (18) (19) (20) (21) . Numerous cytokines are known to work in concert with progesterone to regulate MMP expression in various reproductive processes (22, 23) . For example, the suppression of stromal-specific MMP-3 and epithelial-specific MMP-7 expression during the secretory phase of the menstrual cycle requires both progesterone and transforming growth factor-␤ (16, 24) . In contrast to cytokines that work cooperatively with progesterone to limit MMP expression, inflammatory cytokines may act in opposition to progesterone to stimulate MMP expression. Among such cytokines expressed at the mater-nal-fetal interface, members of the interleukin-1 (IL-1) family are known to regulate MMP expression (25) and appear to play an important role in cellular interactions during the establishment of pregnancy (7, 26) . For example, IL-1␣ expression appears to be linked to elevated levels of MMP-7 messenger ribonucleic acid (mRNA) found in epithelial cells at sites of ectopic pregnancy (27) . Additionally, several laboratories have shown that IL-1 can oppose progesteronedependent differentiation of the specialized endometrial stroma. Using in vitro models of decidualization, studies show that IL-1 can prevent progestin-mediated suppression of MMP-3 (17, 20) , morphological decidualization (28) , and decidual endocrine function (29) .
Clinical observations have demonstrated the importance of adequate progesterone levels for normal maturation of the endometrial stroma in forming the decidua of pregnancy (4, 14, 30, 31) . And, although the IL-1 family appears to play a positive role in implantation (7, 26) , these cytokines are also elevated in association with endometrial breakdown during menstruation (18 -20, 32, 33) and at the time of parturition (34 -37) . Therefore, the ability of inflammatory cytokines to oppose progesterone action has broad and potentially negative ramifications clinically with regard to the successful establishment and maintenance of pregnancy and may play a role in the pathogenesis of other aspects of human infertility as well. Studies to date indicate that a delicate balance exists in steroid-sensitive tissues that serves to regulate tissue responsiveness to inflammatory cytokines, especially cytokines such as IL-1, which have the potential to stimulate MMP expression. In the present study we examined the in vivo and in vitro ability of progesterone to regulate endometrial stromal cell secretion of MMP-3 in response to IL-1␣ challenge. Our results show that endometrial exposure to progesterone, either in vivo or in vitro, induces an insensitivity to IL-1␣, as determined by stromal cell expression of MMP-3 protein and mRNA. This rapid, progesterone-mediated decrease in IL-1␣ sensitivity may ensure the structural integrity of the endometrium and developing placenta despite the invasive events that take place during the establishment of normal pregnancy.
Materials and Methods

Acquisition of human tissue
Endometrial tissues were obtained from a normal donor population of women (aged 21-45 yr) exhibiting regular menstrual cycles. Endometrial thickness of 9 mm or more was determined by pelvic ultrasound before proceeding with biopsy of the uterine fundus using a Pipelle curette (Unimar, Inc., Wilton, CT). Serum progesterone values were determined by immunoassay (38) , with less than 1.5 ng/mL defining the proliferative phase and 1.5 ng/mL or more representing the secretory phase. Tissue was immediately placed in cold phenol red-free DMEM/ Ham's F-12 medium (DME/F-12; Sigma, St. Louis, MO), and washed to remove residual blood and mucus. The use of human tissues was approved by the Vanderbilt University institutional review board and committee for the protection of human subjects.
Experimental media and general culture conditions
All cultures were maintained for the first 24 h in DME/F-12 with 5% charcoal-stripped calf serum (HyClone Laboratories, Inc., Logan, UT) and estradiol (E; 10 Ϫ9 mol/L), and all media were supplemented with 1% insulin-transferrin-selenium-X (Life Technologies, Inc., Gaithersburg, MD), 0.1% Pentex Ex-Cyte III (Bayer Corp., Kankakee, IL), and an antibiotic/antimycotic solution (Hybri-Max, Sigma). Specific experimental medium components are listed in detail below. Cultures were incubated at 37 C in a humidified chamber with 95% air/5% CO 2 . Stock solutions of ␤-estradiol, progesterone (Sigma), and onapristone (Schering AG, Berlin, Germany) were prepared in absolute ethanol and further diluted in experimental medium. The concentrations of additives, unless otherwise noted, were: E alone, 10 Ϫ8 mol/L; estradiol plus progesterone, (EP; E ϭ 10 Ϫ9 mol/L; P, 5 ϫ 10 Ϫ7 mol/L), onapristone (Ona; 5 ϫ 10
Ϫ6
mol/L), and recombinant human IL-1␣ (100 pg/mL; R&D Systems, Inc., Minneapolis MN).
Organ culture of endometrial tissue
After removal of residual blood and mucus, tissue was sectioned into uniform 2 ϫ 2-mm 3 fragments, divided equally, and placed in tissue culture inserts (Millipore Corp., Bedford, MA) as previously described (16) . After the initial 24-h adjustment period, tissue was treated with steroids alone in DME/F-12 medium for 24 h, with IL-1␣ added subsequently to designated groups for an additional 24 h. During radiolabeling of secreted proteins, tissue was changed to methionine-free medium, and experimental treatments were continued throughout the labeling period for a total cytokine exposure of 48 h.
Isolation and culture of endometrial stromal cells
Tissue was enzymatically digested as described previously (39) with minor modification. Briefly, tissue fragments were incubated in medium containing 0.4% type IV collagenase (Worthington Biochemical Corp., Freehold, NJ), 0.02% deoxyribonuclease I, and 2% chicken serum (Sigma) for 1 h at 37 C. Stromal cells were separated from epithelial gland fragments by consecutive filtrations through nylon mesh (Small Parts, Inc., Miami Lakes, FL) of 85 and 20 m pore size. Cell purity was assessed by immunolocalization of cytokeratins; less than 5% contamination by epithelial cells was routinely observed. Stromal cells (2 ϫ 10 5 /well) were plated on a dry film of type IV mouse collagen (Becton Dickinson and Co., Bedford MA) in 48-well tissue culture plates (Falcon, Lincoln Park NJ), with duplicate treatment groups or were grown to confluence in 75-cm 2 tissue culture flasks for total RNA isolation as described below. After the initial 24-h adjustment period, experimental treatments with steroids proceeded for 2-6 days as indicated in DME/ F-12 medium with 3% charcoal-stripped calf serum. Designated experimental groups were challenged with IL-1␣ and continued for 24 h. During radiolabeling of secreted proteins, cells were changed to methionine-free medium, and experimental treatments were continued throughout the labeling period, for a total cytokine exposure of 48 h. Medium changes occurred every 2-3 days for all experimental treatment groups, as appropriate.
Metabolic labeling and analysis of MMP secretion in vitro
Secretion of pro-MMP-3 was analyzed after [ 35 S]methionine labeling (100 Ci/mL) for the last 22 h of culture at 37 C in DMEM/methioninefree medium (ICN Biomedicals, Inc., Aurora, OH) as previously described (16) . Briefly, radiolabeled proteins were quantitated by trichloroacetic acid precipitation, and equivalent trichloroacetic acidprecipitable counts (2 ϫ 10 5 cpm) were immunoprecipitated with a polyclonal antibody directed against a synthetic peptide corresponding to a deduced sequence in the carboxyl-terminus of human pro-MMP-3 (Research Genetics, Inc., Huntsville, AL) that recognizes both the proenzyme and activated forms of MMP-3. The resulting complexes were removed with protein A-Sepharose (Sigma) and identified by SDS-PAGE and autoradiography. Samples from the same experiment were analyzed simultaneously on a single electrophoresis apparatus, with each gel containing positive and negative controls, i.e. E plus IL-1 and EP, respectively.
RNA extraction from cultured endometrial stromal cells
Total RNA was extracted from stromal cells grown to confluence in 75-cm 2 tissue culture flasks for RT-PCR. After culture and treatment, cells were washed twice with phosphate-buffered saline and removed by enzymatic digestion with 0.05% trypsin/0.02% ethylenediamine tetraacetate (Life Technologies, Inc., Grand Island, NY). Cells were sus-pended in 5% charcoal-stripped calf serum to neutralize enzymatic action and centrifuged. RNA was recovered by the single step method of Chomzynski and Sacchi (40, 41) with slight modification. Briefly, the stromal cell pellet was lysed in Tri-Reagent (Molecular Research Center, Inc., Cincinnati, OH), and the homogenate was separated into aqueous and organic phases by the addition of chloroform and centrifugation. RNA is precipitated from the aqueous phase with isopropanol, washed with ethanol, and solubilized in nuclease-free H 2 O (Promega Corp., Madison, WI). Extracted RNA was quantitated by its absorbance at 260 nm.
RT-PCR
Expression of MMP-3 mRNA and the constitutively expressed mitochondrial gene, cytochrome c oxidase subunit I (CO-I) mRNA (42) was analyzed. RT-PCR was carried out with the use of a reagent kit (Access RT-PCR System, Promega Corp., Madison, WI) and a thermal cycler (model PTC-100, MJ Research, Inc., Watertown, MA). Equal amounts of total RNA (50 and 5 ng for MMP-3 and CO-I, respectively) were reverse transcribed per reaction. The sense primer for MMP-3 was ATTTATT-TCTCGTTGCTGCTCATGA, and the antisense primer was TATGTTT-TGTTCTTTTCCTTATCAG, producing a product of 573 bp (43) . MMP-3 RNA was reverse transcribed at 48 C for 45 min, followed by 2.5 min at 94 C to inactivate the enzyme. Second strand complementary DNA synthesis and PCR amplification were carried out for 38 cycles as follows: 1 min at 54 C, 3 min at 68 C, and a final extension step at 68 C for 3 min. Amplification of CO-I was performed in a companion tube to comparatively determine the quantity of the PCR products and confirm the integrity of the RNA. The sense primer for CO-I was CGTCACAGC-CCATGCATTTG, and the antisense primer was GGTTAGGTCTACG-GAGGCTC, producing a product of 268 bp (42) . The number of PCR cycles was within the linear logarithmic phase of the amplification curve. CO-I RNA was reverse transcribed for 45 min at 48 C, followed by inactivation at 94 C for 2.5 min. PCR amplification was carried out for 21 cycles as follows: 1 min at 57 C, 30 s at 70 C, and a final extension step at 70 C for 3 min. DNA contamination was excluded using an amplification mixture containing all reagents except the reverse transcriptase (negative control). In addition, RNA and primers provided with the RT-PCR kit were included in each assay as a positive control. Gel analysis was performed with 18 L of each MMP-3 product and 9 L CO-I product, separated by electrophoresis on a 2% agarose-Tris-borate-ethylenediamine tetraacetate gel, and visualized with the use of ethidium bromide. The sizes of amplified products were compared with molecular weight markers run in parallel. The PCR products were photographed using a Polaroid (Cambridge, MA) system, and exposed films were scanned and analyzed by optometric scanner (model GS-700, BioRad Laboratories, Inc., Hercules, CA), and the integrated optical density in arbitrary units was determined using the Molecular Analyst software (Bio-Rad Laboratories, Inc.). The levels of MMP-3, normalized to the CO-I control value, were calculated, and the results were expressed as relative amounts of mRNA.
Statistical analysis
Analysis of stromal cell data was performed on results obtained from three to eight experiments, as indicated, performed in duplicate and are expressed as the mean Ϯ sem. Immunoprecipitated protein was quantified by excision of each protein band from the polyacrylamide gel and determination of total counts by scintillation detection. Statistical analysis was performed by paired t test (44) . P Ͻ 0.05 was considered significant.
Results
Steroid and cytokine regulation of MMP-3 in endometrial organ culture
In a previous study we demonstrated that the simultaneous addition of IL-1␣ to organ cultures of proliferative phase human endometrium treated with either E or EP, resulted in stimulation of MMP-3 expression (45). We proposed that a stimulation of local endometrial MMP expression by this inflammatory cytokine at the site of implantation could destabilize the endometrium and interfere with the establishment of a normal pregnancy. Therefore, the goal of the current study was to determine whether prior progesterone exposure in vivo or in vitro might influence the subsequent impact of IL-1␣ on MMP-3 expression. In preliminary experiments we exposed proliferative phase endometrial tissue to EP for 24 h in organ culture before challenge with IL-1␣. As shown in Fig. 1A , exposure of this tissue to IL-1␣ resulted in increased MMP-3 secretion despite the presence of progesterone preceding the cytokine challenge (compare lanes 1 and 2) . This finding supports our previous study (45) and indicates that short term exposure to progesterone is not able to prevent IL-1␣-mediated stimulation of MMP-3 expression in organ cultures established from proliferative phase endometrial tissue. However, in contrast to a high degree of IL-1␣ sensitivity in proliferative phase endometrium, we observed that responsiveness to this cytokine was dramatically diminished in tissue obtained during the secretory phase of the cycle. As shown in Fig. 1B , endometrial tissue obtained during the early secretory phase (serum progesterone values Ͼ 1.5 ng/mL) and placed in an identical organ culture system was unresponsive to IL-1␣ stimulation of MMP-3 (compare lanes 1 and 2). In further support of this finding, 11 of 13 additional endometrial samples examined throughout the early and midsecretory phase of the cycle (serum progesterone values of 1.6 -28.5 ng/mL) showed a consistent absence of responsiveness to IL-1␣, as determined by the loss of MMP-3 stimulation (data not shown). Together these results indicate that although proliferative phase endometrium remains sensitive to IL-1␣ after short term exposure of organ cultures to progesterone, in vivo exposure to this steroid in the secretory phase of the cycle appears to substantially reduce tissue sensitivity to IL-1␣.
Loss of sensitivity to IL-1␣ in isolated stromal cells is progesterone dependent
Results from our organ culture study clearly demonstrated that progesterone exposure in vivo resulted in a loss of IL-1␣ responsiveness relative to MMP-3 secretion. However, short term organ culture of proliferative endometrium in the presence of progesterone did not induce a loss of sensitivity to IL-1␣. Although we interpret this finding to indicate that a longer exposure to progesterone may be required to alter responsiveness to IL-1, it is also likely that interactions among multiple cell types in the organ culture system may complicate this experimental approach. Several laboratories, including ours, have used isolated endometrial stromal cells to demonstrate that progesterone suppression of MMP-3 mRNA and protein expression in vitro can be antagonized by IL-1␣ or IL-␤ (17, 20, 27, 45, 46) . Therefore, to circumvent the potential limitation of using short term organ cultures of endometrial tissue, we investigated progesterone regulation of cytokine action further in isolated stromal cells. In these experiments, stromal cells were purified from proliferative phase biopsies to eliminate prior exposure to progesterone in vivo. As shown in Fig. 2, A and B, without steroid support in vitro (steroid free), MMP-3 levels remain low, while addition of IL-1␣ induces the maximum increase in MMP-3 secretion observed in this culture system. Although a high stimulation of MMP-3 secretion was obtained under steroid-free conditions, the absence of steroids does not reflect the normal steroid physiology of the secretory endometrium but, rather, correlates with conditions found during menstruation (32, 46) . As maintenance of stromal cells in E alone results in expression of MMP-3 similar to that found in the steroid-free group, we chose the stimulation index observed in the E group vs. the E plus IL-1␣ (EϩIL-1) group as the positive control for our model system. Reflective of data obtained in organ culture of proliferative phase tissue, IL-1␣ treatment of isolated stromal cells in the presence of E (EϩIL-1) stimulates the secretion of MMP-3 approximately 2-fold. However, in contrast to results obtained with organ cultures of proliferative endometrium, the addition of progesterone (EP) to isolated stromal cells both suppressed MMP-3 expression (E vs. EP groups) and significantly inhibited (P ϭ 0.02) the ability of IL-1␣ (EPϩIL-1) to stimulate the expression of MMP-3 (EϩIL-1 vs. EP ϩIL-1 groups) . The ability of progesterone to suppress IL-1␣ stimulation of MMP-3 in isolated stromal cells was also demonstrated at the level of messenger RNA expression. As shown in Fig. 2 , C and D, MMP-3 mRNA expression by stromal cells cultured under comparable conditions parallels that of protein secretion. More specifically, stromal cells treated with E alone exhibit elevated levels of MMP-3 mRNA expression compared to treatment with EP, which shows total suppression, and subsequent treatment of either group with IL-1␣ (EϩIL-1 vs. EPϩIL-1) did not alter the pattern of MMP-3 mRNA expression.
The above results suggest an important role for progesterone in reducing endometrial sensitivity to IL-1␣ stimulation of MMP-3 during the secretory phase of the menstrual cycle. Therefore, to explore the temporal boundaries of IL-1␣ loss of sensitivity, cells were treated with EP for 2, 4, or 6 days, followed by IL-1␣ challenge. The results shown in Fig.  3 , A and B, demonstrate that a reduction in IL-1␣ responsiveness can be induced in purified stromal cells in as little as 2 days and maintained in vitro for a minimum of 6 days compared to the positive control (EϩIL-1). To determine whether the loss of sensitivity to IL-1␣ requires the binding of progesterone to the progesterone receptor, stromal cells were treated with the progesterone antagonist, onapristone, at the time of IL-1␣ challenge. Onapristone has been shown by other investigators to antagonize progesterone action in isolated endometrial cells (32, 47) . The results of these experiments are shown in Fig. 4, A and B , and indicate that blocking the progesterone receptor with onapristone partially reduces the ability of progesterone to decrease stromal cell sensitivity to IL-1␣.
Taken together, the results observed in isolated stromal cells suggest that progesterone is responsible for limiting IL-1␣ responsiveness in endometrial stromal cells. Clinically, reduced ovarian progesterone production, as found in luteal phase defect (48, 49) , has been linked to pregnancy loss (4, 50) , whereas the overexpression of inflammatory cytokines, including IL-1, has been implicated in preterm labor (36) . Therefore, we next examined the concentration-dependent nature of progesterone and IL-1␣ regulation of MMP-3 expression. As shown in Fig. 5, A and B, treatment of stromal cells with decreasing progesterone concentrations (5 ϫ 10
Ϫ9 mol/L) resulted in a return of IL-1␣ sensitivity, as indicated by increasing MMP-3 secretion. In contrast to the results obtained by varying progesterone concentrations, stromal cells exposed to increasing levels of IL-1␣ (100 pg/ml to 30 ng/ml) showed no increase in MMP-3 secretion as long as a constant level of progesterone was maintained (5 ϫ 10 Ϫ7 mol/L; data not shown). These results suggest that endometrial responsiveness to IL-1␣ stimulation of MMP-3 is more sensitive to fluctuating progesterone levels than to changes in cytokine exposure. Although IL-1 has been shown to antagonize progesterone regulation of MMPs by a number of laboratories (17, 20, 27, 45, 46) , the current results demonstrate that prior progesterone exposure may prevent stimulation of MMPs by inflammatory cytokines in the normal secretory endometrium.
Discussion
The MMPs represent a large family of extracellular matrixdegrading enzymes expressed during normal reproductive processes that require the physical breakdown or restructuring of tissue. Members of the stromelysin family, including MMP-3, MMP-7, and MMP-11, are focally expressed by endometrial stromal and epithelial cells during estrogenmediated growth and are broadly expressed during tissue breakdown in association with menstruation (18, 51, 52) . A number of recent studies have shown that progesterone acts to suppress stromal and epithelial cell-specific MMP expression during the secretory phase of the menstrual cycle (16, 19, 24, 32) . The specialized stromal cells of the endometrium are directly dependent upon progesterone to become morphologically and functionally differentiated, a biological process known as decidualization (30) . Importantly, as the decidua of pregnancy, stromal cells are believed to limit trophoblast invasion at the maternal-fetal interface in part through inhibition of local endometrial MMP expression (12) (13) (14) . For example, the absence of a normal decidua basalis found in placenta accreta (53) may compromise the normal control mechanisms of trophoblast invasion, resulting in hyperinvasion and the risk of incomplete placental detachment at parturition. Among infertility patients, inadequate progesterone production and compromised stromal cell decidualization are cited as factors in failed implantation, recurrent spontaneous abortion, and placental defects (4, 50, 53) . Clearly, the ability of progesterone to coordinate endometrial receptivity and decidualization is essential for successful embryo attachment, implantation, and establishment of the hemochorial placenta (1-3) .
Although locally produced cytokines often act cooperatively with steroids to regulate specific endometrial functions (5, 6, 21) , inflammatory cytokines have been shown to oppose progesterone action. For example, IL-1 or TNF-␣ can prevent the decidualized stromal cell release of prolactin (28, 54, 55) and renin (29) in vitro. Several laboratories, including our group, have demonstrated the ability of IL-1 to oppose progesterone regulation of endometrial MMPs, (16, 17, 19, 20, 45, 56) . However, the present study reveals that a novel and temporally ordered interrelationship exists, by which prior steroid exposure can limit the response of endometrial stromal cells to IL-1␣. We find that progesterone exposure in vivo greatly reduces the subsequent responsiveness of endometrial tissue to IL-1␣-stimulated MMP-3 expression in organ culture, essentially blocking stimulation of MMP-3 in response to this cytokine. Furthermore, our in vitro model using isolated cells demonstrates that progesterone can act directly on stromal cells to reduce cellular sensitivity to IL-1␣. Human stromal cells isolated during the proliferative phase of the menstrual cycle and exposed to progesterone in vitro developed a resistance to subsequent IL-1␣ stimulation of MMP-3 secretion. This acquired loss of stromal cell sensitivity to IL-1␣ occurred very rapidly in vitro, requiring as little as 2-day exposure to progesterone, and could be blocked by treatment with onapristone, a progesterone receptor antagonist. In addition to effects on MMP-3 protein secretion, progesterone suppression of MMP-3 mRNA stimulation by IL-1␣ was demonstrated, suggesting that steroid regulation occurs at the level of transcription. Given these results, it is reasonable to speculate that progesterone mediates a local loss of sensitivity to IL-1␣ stimulation of MMP-3 in the endometrium during the midsecretory phase of the cycle when the endometrium is most receptive to embryo implantation.
It is important to note that implantation normally occurs when levels of IL-1␣ and the IL-1 type I receptor are elevated in endometrial glandular epithelium (57, 58) . Furthermore, some investigators have suggested that members of the IL-1 family are essential for normal maternal-fetal interactions (7), and successful implantation has been linked to the release of IL-1␣ by human embryos in vitro (26) . It appears somewhat paradoxical that local IL-1 expression is elevated at this time, yet this cytokine has the ability to oppose progesteronemediated stromal cell decidualization (28, 54, 55) . However, the results of the current study address this contradiction, as progesterone levels are normally elevated for 5-7 days before the local embryonic or epithelial cell release of IL-1. Furthermore, at the time of implantation, a decrease in progesterone receptor concentration has been identified in the luminal and glandular epithelium of multiple species, including humans (59 -63) . It is possible that a transient decrease in progesterone receptor concentration in luminal epithelial cells may be necessary to allow focal MMP stimulation by IL-1 or other paracrine mediators during initial endometrial penetration by trophoblast cells. Whether IL-1␣ acts to stimulate MMP-3, MMP-7, or other maternal MMPs during the establishment of normal human pregnancy is not entirely clear at this juncture, although our laboratory has found that MMP-7 mRNA is elevated in association with IL-1␣ expression at ectopic sites of pregnancy (27) . Interestingly, the antiprogestins onapristone and RU-486 are ineffective in the treatment of ectopic pregnancy (64) , possibly due to reduced stromal cell decidualization at ectopic sites (65, 66) . More relevant, however, is that the results reported here are consistent with the ability of antiprogestins to interfere with progesterone suppression of MMP-3 and MMP-9 (32, 47), and represent a mechanism for pregnancy termination by progestin antagonists. The presence of members of the IL-1 family at the maternal-fetal interface suggests a potentially rapid mechanism for broad MMP expression, resulting in pregnancy termination and expulsion of the products of conception in the event of a failed pregnancy. In support of this possibility, our study demonstrates that reducing stromal cell sensitivity to IL-1␣ with progesterone is a dose-dependent process, requiring constant steroid support in vitro. The ability of IL-1␣ to stimulate MMP-3 was progressively greater as progesterone levels were decreased in vitro below those representative of the mid-secretory phase of the menstrual cycle and early pregnancy (5 ϫ 10 Ϫ7 -10 Ϫ9 mol/L). In summary, the current study suggests an important progesterone-dependent mechanism to limit the expression of endometrial MMPs in response to inflammatory cytokines such as IL-1␣. As illustrated in Fig. 6 , IL-1␣ may be released by endometrial epithelium, immune cells, or invasive trophoblasts and is capable of stimulating MMP-3 in proliferative phase stromal cells. After exposure to progesterone, however, differentiated stromal cells become insensitive to cytokine-mediated MMP-3 stimulation. Although this response can be observed after progesterone exposure either in vivo or in vitro, the precise mechanisms controlling the expression of specific MMPs at the maternal-fetal interface, which contains both stimulators and suppressors of these enzymes, remain to be elucidated. Future studies are needed to reveal the downstream effectors that mediate the responses of differentiated stromal cells to both progesterone and IL-1 relative to MMP-3 expression. Nevertheless, the loss of sensitivity demonstrated by endometrial stromal cells to inflammatory cytokines that participate in the normal maternal-fetal communication of pregnancy would probably contribute to the stability of the uterine environment during implantation and placentation. A shift in the equilibrium during pregnancy failure due to inadequate progesterone action may promote increased inflammatory cytokine responsiveness and provide a mechanism for the up-regulation of MMP expression, resulting in placental breakdown and detachment. A better understanding of how the endometrium acts to minimize MMP expression during the establishment of pregnancy may potentially contribute to improved treatments for infertility, placental defects, and pregnancy loss. 
